Nothing Special   »   [go: up one dir, main page]

SV2017005393A - Anticuerpos anti-vasa y mã‰todos de producciã“n y uso de los mismos - Google Patents

Anticuerpos anti-vasa y mã‰todos de producciã“n y uso de los mismos

Info

Publication number
SV2017005393A
SV2017005393A SV2017005393A SV2017005393A SV2017005393A SV 2017005393 A SV2017005393 A SV 2017005393A SV 2017005393 A SV2017005393 A SV 2017005393A SV 2017005393 A SV2017005393 A SV 2017005393A SV 2017005393 A SV2017005393 A SV 2017005393A
Authority
SV
El Salvador
Prior art keywords
mabs
vasa
vase
methods
cdrs
Prior art date
Application number
SV2017005393A
Other languages
English (en)
Inventor
David T Weaver
Bo Zhang
Original Assignee
Ovascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovascience Inc filed Critical Ovascience Inc
Publication of SV2017005393A publication Critical patent/SV2017005393A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE DIVULGAN ANTICUERPOS ANTI-VASA (MABS), PARTICULARMENTE MABS HUMANIZADOS QUE SE UNEN ESPEC�FICAMENTE A VASA CON ALTA AFINIDAD. SE PROPORCIONAN LAS SECUENCIAS DE AMINO�CIDOS DE LOS CDRS DE CADENAS LIGERAS Y CADENAS PESADAS, AS� COMO SECUENCIAS DE CONSENSO PARA ESTOS CDRS, DE ESTOS MABS ANTI-VASA. LA DIVULGACIÓN TAMBIÉN PROPORCIONA MOLÉCULAS DE �CIDO NUCLEICO QUE CODIFICAN LOS MABS ANTI-VASA, VECTORES DE EXPRESIÓN, CÉLULAS HUÉSPED, MÉTODOS PARA HACER LOS MABS ANTI-VASA Y MÉTODOS PARA EXPRESAR LOS MABS ANTI-VASA. FINALMENTE, SE DIVULGAN MÉTODOS PARA USAR LOS MABS ANTI-VASA PARA AISLAR Y/O PURIFICAR LAS CÉLULAS QUE EXPRESAN VASA
SV2017005393A 2014-09-16 2017-02-23 Anticuerpos anti-vasa y mã‰todos de producciã“n y uso de los mismos SV2017005393A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US201462089054P 2014-12-08 2014-12-08
PCT/US2015/050449 WO2016044436A2 (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Publications (1)

Publication Number Publication Date
SV2017005393A true SV2017005393A (es) 2017-06-07

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005393A SV2017005393A (es) 2014-09-16 2017-02-23 Anticuerpos anti-vasa y mã‰todos de producciã“n y uso de los mismos

Country Status (26)

Country Link
US (4) US9403913B2 (es)
EP (1) EP3194448A4 (es)
JP (2) JP2017532953A (es)
KR (1) KR20170056521A (es)
CN (1) CN106573985A (es)
AP (1) AP2017009758A0 (es)
AU (1) AU2015317813B2 (es)
BR (1) BR112017003263A2 (es)
CA (1) CA2959179A1 (es)
CL (1) CL2017000402A1 (es)
CO (1) CO2017001724A2 (es)
CR (1) CR20170067A (es)
DO (1) DOP2017000050A (es)
EA (1) EA201790236A1 (es)
EC (1) ECSP17011262A (es)
GT (1) GT201700036A (es)
IL (1) IL250451A0 (es)
MX (1) MX358243B (es)
NI (1) NI201700022A (es)
PE (1) PE20170667A1 (es)
PH (1) PH12017500309A1 (es)
SG (1) SG11201701016WA (es)
SV (1) SV2017005393A (es)
TN (1) TN2017000066A1 (es)
TW (1) TW201619194A (es)
WO (1) WO2016044436A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110122881A (ko) 2006-04-07 2011-11-11 워너 칠콧 컴퍼니 엘엘씨 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER
JP2017532953A (ja) * 2014-09-16 2017-11-09 オバサイエンス・インコーポレイテッド 抗ｖａｓａ抗体、ならびにその産生法および使用法
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
WO2021096829A1 (en) * 2019-11-11 2021-05-20 Vanderbilt University Human monoclonal antibodies to hantavirus and methods of use therefor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039518A1 (en) * 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
EP1233978A4 (en) 1999-11-18 2003-07-23 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
EP3498827A1 (en) 2004-05-17 2019-06-19 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
EP2314317A3 (en) * 2004-07-09 2011-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
EP2208783A1 (en) * 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
EP2336311A4 (en) 2008-09-25 2012-07-04 Univ Tokyo Nat Univ Corp ANTI-VASA ANTIBODY OF TUNA
SG172427A1 (en) * 2008-12-26 2011-07-28 Univ Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
CN102574915B (zh) * 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
EP2787073B1 (en) 2011-04-14 2019-03-20 The General Hospital Corporation Compositions and methods for autologous germline mitochondrial energy transfer
AU2012276038B2 (en) * 2011-06-29 2017-08-31 President And Fellows Of Harvard College Compositions and methods for enhancing bioenergetic status in female germ cells
WO2014106235A1 (en) * 2012-12-31 2014-07-03 Development Center For Biotechnology Anti-granulysin antibodies and methods of use thereof
JP2017532953A (ja) * 2014-09-16 2017-11-09 オバサイエンス・インコーポレイテッド 抗ｖａｓａ抗体、ならびにその産生法および使用法
AU2016206945A1 (en) * 2015-01-13 2017-08-10 President And Fellows Of Harvard College Purification of germ stem cells by targeting MRP9

Also Published As

Publication number Publication date
CR20170067A (es) 2017-05-10
CA2959179A1 (en) 2016-03-24
US20160311929A1 (en) 2016-10-27
PE20170667A1 (es) 2017-06-06
AU2015317813B2 (en) 2018-04-05
JP2017532953A (ja) 2017-11-09
IL250451A0 (en) 2017-03-30
SG11201701016WA (en) 2017-03-30
US9567404B2 (en) 2017-02-14
MX2017002390A (es) 2017-07-28
AP2017009758A0 (en) 2017-02-28
MX358243B (es) 2018-08-10
DOP2017000050A (es) 2018-04-15
JP2018148915A (ja) 2018-09-27
NI201700022A (es) 2017-05-04
EP3194448A4 (en) 2018-03-14
ECSP17011262A (es) 2017-05-31
TW201619194A (zh) 2016-06-01
GT201700036A (es) 2018-12-19
WO2016044436A3 (en) 2016-06-09
AU2015317813A1 (en) 2017-03-02
EA201790236A1 (ru) 2017-11-30
BR112017003263A2 (pt) 2017-11-28
WO2016044436A2 (en) 2016-03-24
TN2017000066A1 (en) 2018-07-04
US20180155445A1 (en) 2018-06-07
EP3194448A2 (en) 2017-07-26
KR20170056521A (ko) 2017-05-23
CN106573985A (zh) 2017-04-19
CO2017001724A2 (es) 2017-07-19
US20160075797A1 (en) 2016-03-17
PH12017500309A1 (en) 2017-07-10
US9403913B2 (en) 2016-08-02
US20170107299A1 (en) 2017-04-20
CL2017000402A1 (es) 2017-11-03

Similar Documents

Publication Publication Date Title
SV2017005393A (es) Anticuerpos anti-vasa y mã‰todos de producciã“n y uso de los mismos
CL2017002820A1 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CO2017013398A2 (es) Anticuerpos anti-ctla-4
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
EA201690529A1 (ru) Способы модификации клетки-хозяина
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
MX2016016886A (es) Anticuerpos anti-axl.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
AR110677A1 (es) Anticuerpos anti-c1s y métodos para usarlos
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
BR112015000982B8 (pt) Método para a obtenção de uma molécula de ácido nucleico sintético
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
CL2019002894A1 (es) Anticuerpo monoclonal para pd-l1.
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
EA201992006A1 (ru) Пусковая система и способ повышения эффективности электроантимагнитных пусковых систем
UY37377A (es) Anticuerpos multiespecíficos que facilitan el emparejamiento selectivo de cadenas ligeras
SV2016005302A (es) Tinturas reactivas fluorescentes, proceso para su producción y su uso
CL2017001633A1 (es) Método de manufactura de proteína.
CL2020000920A1 (es) Anticuerpo monoclonal anti-il-5ra.
BR112017022635A2 (pt) anticorpo de igf-1r e seu uso para diagnóstico de câncer
BR112016017597A2 (pt) Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo